Blood:Trib1通过调节Hoxa9的转录来促进AML进展

2020-08-10 MedSci原创 MedSci原创

在髓系白血病发生过程中已观察到Trib1对Hoxa9的密切遗传作用,其中Trib1过表达可明显加速Hoxa9诱导的白血病发生。但Trib1如何功能性调节Hoxa9转录活性的潜在机制尚不清楚。

中心点:

Trib1可通过降解C/EBPα和修饰与Hoxa9相关的超级增强子来影响髓样白血病发生中的Hoxa9;

Erg是Trib1和Hoxa9的关键靶标,对BRD4抑制有反应,并在白血病发生中起关键作用。

摘要:

假激酶Trib1充当髓样癌基因,将E3泛素连接酶COP1募集到C/EBPa上,并与MEK1相互作用以增强ERK磷酸化。在髓系白血病发生过程中已观察到Trib1对Hoxa9的密切遗传作用,其中Trib1过表达可明显加速Hoxa9诱导的白血病发生。但Trib1如何功能性调节Hoxa9转录活性的潜在机制尚不清楚。

在本研究中,Yoshino等证实Trib1调节与Hoxa9相关的超级增强子

ChIP-seq分析显示,Erg、Spns2、Rgl1和Pik3cd基因座的超级增强子处的组蛋白H3K27Ac信号增强,且伴随这些基因的mRNA表达增加。超级增强子活性的修饰主要通过Trib1降解C/EBPa p42来实现,而MEK/ERK通路的贡献较小。沉默Erg可消除Trib1过表达所获得的增长优势,表明Erg是Trib1 /Hoxa9轴的关键下游靶标。

此外,用BRD4抑制剂JQ1治疗急性髓细胞性白血病(AML)细胞在体外和体内均表现为Trib1/Erg依赖性的生长抑制。在人AML细胞系中也观察到了TRIB1引起的ERG上调,提示Trib1是Hoxa9相关AML的潜在治疗靶标。

综上所述,该研究揭示了在髓样白血病发生过程中,Trib1调节染色质和Hoxa9驱动的转录的新机制

原始出处:

Seiko Yoshino,et al. Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9. Blood. July 30, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747404, encodeId=11f21e4740463, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jun 08 16:29:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530222, encodeId=61111530222c6, content=<a href='/topic/show?id=9bd19050a2' target=_blank style='color:#2F92EE;'>#HoxA9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9050, encryptionId=9bd19050a2, topicName=HoxA9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b412069132, createdName=mjldent, createdTime=Wed Aug 12 02:29:03 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807277, encodeId=e9c380e277c8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Aug 10 14:40:16 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807260, encodeId=f42480e260f6, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Mon Aug 10 12:03:15 CST 2020, time=2020-08-10, status=1, ipAttribution=)]
    2021-06-08 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747404, encodeId=11f21e4740463, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jun 08 16:29:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530222, encodeId=61111530222c6, content=<a href='/topic/show?id=9bd19050a2' target=_blank style='color:#2F92EE;'>#HoxA9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9050, encryptionId=9bd19050a2, topicName=HoxA9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b412069132, createdName=mjldent, createdTime=Wed Aug 12 02:29:03 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807277, encodeId=e9c380e277c8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Aug 10 14:40:16 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807260, encodeId=f42480e260f6, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Mon Aug 10 12:03:15 CST 2020, time=2020-08-10, status=1, ipAttribution=)]
    2020-08-12 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747404, encodeId=11f21e4740463, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jun 08 16:29:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530222, encodeId=61111530222c6, content=<a href='/topic/show?id=9bd19050a2' target=_blank style='color:#2F92EE;'>#HoxA9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9050, encryptionId=9bd19050a2, topicName=HoxA9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b412069132, createdName=mjldent, createdTime=Wed Aug 12 02:29:03 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807277, encodeId=e9c380e277c8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Aug 10 14:40:16 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807260, encodeId=f42480e260f6, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Mon Aug 10 12:03:15 CST 2020, time=2020-08-10, status=1, ipAttribution=)]
    2020-08-10 ms3000000449926787

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1747404, encodeId=11f21e4740463, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Jun 08 16:29:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530222, encodeId=61111530222c6, content=<a href='/topic/show?id=9bd19050a2' target=_blank style='color:#2F92EE;'>#HoxA9#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9050, encryptionId=9bd19050a2, topicName=HoxA9)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46b412069132, createdName=mjldent, createdTime=Wed Aug 12 02:29:03 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807277, encodeId=e9c380e277c8, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Mon Aug 10 14:40:16 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807260, encodeId=f42480e260f6, content=优秀, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=qinqiyun, createdTime=Mon Aug 10 12:03:15 CST 2020, time=2020-08-10, status=1, ipAttribution=)]
    2020-08-10 qinqiyun

    优秀

    0

相关资讯

Eur J Cancer:HOXA9 meth-ctDNA可作为BRCA突变卵巢癌的生物标志物

聚(ADP-核糖)聚合酶(PARP)抑制剂已成为BRCA突变卵巢癌(OC)的一种新的治疗选择;然而,反应是可变的,并且缺乏预后和预测性生物标志物。因此,我们研究了循环肿瘤DNA(meth-ctDNA)